+Search query
-Structure paper
Title | Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations. |
---|---|
Journal, issue, pages | J. Med. Chem., Vol. 67, Page 1734-1746, Year 2024 |
Publish date | Sep 29, 2023 (structure data deposition date) |
Authors | Tyhonas, J.S. / Arnold, L.D. / Cox, J.M. / Franovic, A. / Gardiner, E. / Grandinetti, K. / Kania, R. / Kanouni, T. / Lardy, M. / Li, C. ...Tyhonas, J.S. / Arnold, L.D. / Cox, J.M. / Franovic, A. / Gardiner, E. / Grandinetti, K. / Kania, R. / Kanouni, T. / Lardy, M. / Li, C. / Martin, E.S. / Miller, N. / Mohan, A. / Murphy, E.A. / Perez, M. / Soroceanu, L. / Timple, N. / Uryu, S. / Womble, S. / Kaldor, S.W. |
External links | J. Med. Chem. / PubMed:38267212 |
Methods | X-ray diffraction |
Resolution | 1.737 - 2.829 Å |
Structure data | PDB-8udt: PDB-8udu: PDB-8udv: |
Chemicals | ChemComp-MLT:
ChemComp-WGF: ChemComp-HOH: ChemComp-CL:
ChemComp-WIQ: ChemComp-SO4: ChemComp-EDO: |
Source |
|
Keywords | TRANSFERASE/INHIBITOR / FGFR inhibitor / Covalent Drug / KIN-3248 / alteration / mutation / structure-based drug design / kinase inhibitor / signaling / proliferation / TRANSFERASE / TRANSFERASE-INHIBITOR complex |